Patient_Reported_Outcome_Measures_in_Rheumatic_Diseases

295 major domains in SSc. They include skin involvement, calcinosis, diffi culties sleeping, hand mobility, dyspnea, eating, bow ...

296 In 2009, Khanna et al. refi ned and improved upon the SSc-GIT 1.0 to create the University of California, Los Angeles, Scler ...

297 The Disabilities of the Arm, Shoulder and Hand (DASH) is a PRO-measuring upper-extremity functional ability in musculoskelet ...

298 pain and can be a component of other assessments such as the SHAQ or SBI. Scoring depends on the type of scale used, but, fo ...

299 [ 84 ]; however, predictive validity has not been examined in SSc. Both the TDI and BDI are able to detect change [ 89 , 90 ...

300 because each scale needs to be devel oped and validated independently [ 96 ]. Moreover, the various PROs available make it d ...

301 Conclusion SSc is a chronic connective tissue disease with many possible manifestations. The effects of SSc are often debili ...

302 Ouimet JM, Pope JE, Gutmanis I, Koval J. Work disability in scleroderma is greater than in rheumatoid arthritis and is pred ...

303 Malcarne VL, Fox RS, Mills SD, Gholizadeh S. Psychosocial aspects of systemic sclerosis. Curr Opin Rheumatol. 2013;25:707–1 ...

304 Khanna D, Furst DE, Clements PJ, Park GS, Hays RD, Yoon J, et al. Responsiveness of the SF-36 and the Health Assessment Que ...

305 Baron M, Hudson M, Steele R, Lo E. Canadian Scleroderma Research G. Validation of the UCLA Scleroderma Clinical Trial Gastr ...

306 Thompson AE, Shea B, Welch V, Fenlon D, Pope JE. Calcium channel blockers for Raynaud’s phenomenon in progressive systemic ...

307 Cella D, Yount S, Rothrock N, Gershon R, Cook K, Reeve B, Ader D, et al. The Patient- Reported Outcomes Measurement Informa ...

© Springer International Publishing Switzerland 2016 309 Y. El Miedany (ed.), Patient Reported Outcome Measures in Rheumatic Dis ...

310 in children as part of the spectrum of juvenile rheumatoid arthritis. In concordance with most of the infl ammatory arthriti ...

311 Diagnosis The diagnosis of SS is often challenging, hence it is not infrequently overlooked. Initially, the diagnosis requir ...

312 (anti-TNF)—infl iximab and etanercept—also did not show signifi cant improve- ments. Of the biologic DMARDS, the anti-B lymp ...

313 Patient-Reported Outcome Measures in Sjögren’s Syndrome Patient-reported outcome measures (PROMs) are patient-self-completed ...

314 (CNS), hematological, glandular, constitutional, lymphadenopathic, and biological ( Appendix 1 ). The ESSDAI is now in use a ...

315 Another generic tool is the Euro-QOL [ 26 ]. The tool comprises fi ve domains: mobility, self-care, usual activities, pain/ ...